Abstract: A pharmaceutical composition includes an NAG-1 inhibitor as an active ingredient for inhibiting resistance against an anticancer drug of an ovarian cancer patient and a method of diagnosing prognosis of resistance against an anticancer drug of an ovarian cancer patient by using the NAG-1 inhibitor. It is found by controlling NAG-1 protein that NAG-1, which is overexpressed in an ovarian cancer patient and in an ovarian cancer stem cell having resistance against an anticancer drug, plays a key role in a chronic inflammatory reaction and resistance against an anticancer drug, and in this regard, NAG-1 can be used as a target gene for effective tumor therapy.

Abstract: The present invention relates to a cell which is genetically modified with respect to its wild type and which comprises a gene sequence coding for a fluorescent protein, wherein the expression of the fluorescent protein depends on the amount of protein that is secreted across the cytoplasmic membrane into the extracytosolic space.

Abstract: Presently described are engineered microbes modified such that the surface of the microbe contains one or more rare earth element (REE) binding ligands, as well as methods of use thereof.

Abstract: A vector is provided that includes a nucleotide sequence selected from any one of (a) to (d). The selection of (a) to (d) includes: (a) the nucleotide sequence set forth in SEQ ID NO: 12, 15, 18, or 21, (b) the nucleotide sequence complementary to the nucleotide sequence set forth in SEQ ID NO: 12, 15, 18, or 21, where (a) and (b) hybridize under stringent conditions, (c) the nucleotide sequence having 90% or more sequence identity with the nucleotide sequence set forth in SEQ ID NO: 12, 15, 18, or 21, and (d) the nucleotide sequence set forth in SEQ ID NO: 12, 15, 18, or 21 in which a total of 1 to 50 nucleotides are substituted, deleted, or inserted.

Abstract: The present invention relates to methods, systems and kits for the diagnosis, prognosis, and treatment of bladder cancer in a subject. The invention also provides biomarkers that define subgroups of bladder cancer, clinically useful classifiers for distinguishing bladder cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping bladder cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping bladder cancer in a subject. Classifiers for subtyping a bladder cancer are provided. Methods of treating bladder cancer based on molecular subtyping are also provided.

Abstract: The present disclosure provides methods and systems directed to cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.

Abstract: Products, systems, and methods for classifying human colorectal cancer into a consensus molecular subtype (CMS) and for assessing risk of recurrence based on CMS scores and based on risk scores derived from abbreviated gene expression profiles, for determining suitable treatment protocols for human colorectal cancer patients based on the determined CMS classification and based on the determined risk of recurrence, and for administering the suitable treatment protocols.

Abstract: This disclosure relates to methods and kits for karyotyping in which chromosomes are interrogated by amplifying loci that are not within copy number variable regions thereof.

Abstract: The invention refers to a method for in vitro diagnosis of a severe infection comprising determining delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein in a biological sample wherein an elevated level of expression of delta-like ligand 1 protein or a nucleotide sequence coding for delta-like ligand 1 protein is indicative of a severe infection; and the use of delta-like ligand 1 protein as a biomarker for in vitro diagnosis of a severe infection such as sepsis.

Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. Preferably, the alcohol is ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.

Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid.

Abstract: An episomal plasmid comprising a gene of interest (GOI) and an autonomously replicating sequence (ARS) which is not operably linked to the GOI, which ARS comprises or consists of a nucleotide sequence identified as any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6-11, or a functionally active variant of any of the foregoing which is characterized by at least 60% sequence identity thereto.

Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule.

Abstract: This invention relates to metabolically engineered microorganisms, such as bacterial and or fungal strains, and bioprocesses utilizing such strains. These strains enable the dynamic control of metabolic pathways, which can be used to optimize production. Dynamic control over metabolism is accomplished via a combination of methodologies including but not limited to transcriptional silencing and controlled enzyme proteolysis. These microbial strains are utilized in a multi-stage bioprocess encompassing at least two stages, the first stage in which microorganisms are grown and metabolism can be optimized for microbial growth and at least one other stage in which growth can be slowed or stopped, and dynamic changes can be made to metabolism to improve the production of desired product, such as a chemical or fuel.

Abstract: Methods, compositions, and kits for high throughput DNA assembly reactions in vitro. Modular CRISPR DNA constructs comprising modular insert DNA parts flanked by cloning tag segments comprising pre-validated CRISPR protospacer/protospacer adjacent motif sequence combinations. High throughput methods of CRISPRi and CRISPRa.

Abstract: The disclosure is directed to nucleic acid, host cell, and polypeptide compositions encoded by the unicellular green alga Chromochloris zofingiensis, methods of making such compositions, and method of using the compositions to produce astaxanthin.

Abstract: A method for producing a fibroin-like protein is provided. A fibroin-like protein is produced by a method of culturing Escherichia coli having a gene encoding the fibroin-like protein in a medium, inducing expression of the gene encoding the fibroin-like protein, and collecting the fibroin-like protein, wherein accumulation of an organic acid at the time of inducing the expression is reduced, and wherein the gene is expressed under control of a tryptophan promoter.

Abstract: By a genome-wide gene analysis of expression profiles of known or putative gene sequences in peripheral blood and biopsy samples, the present inventors have identified a consensus set of gene expression-based molecular biomarkers for distinguishing liver transplantation patients who have Acute Rejection (AR), Hepatitis C Virus Recurrence (HCV-R), both AR/HCV-R, or Acute Dysfunction No Rejection (ADNR). These molecular biomarkers are useful for diagnosis, prognosis and monitoring of liver transplantation patients.

Abstract: Aspects of this disclosure relate to liquid-based workflows for strain engineering. In strain engineering, cells undergo a modification process to acquire a desired change or changes in the cells. Some of the cells accept the change or changes and some do not. Provided herein are liquid-based methods for selecting the population of cells that have accepted the change or changes. Also provided herein are liquid-based methods for removing markers from transformed cells and liquid-based methods for isolating clonally pure populations of cells.